UnitedHealth Group vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Minnetonka US largest healthcare company (NYSE: UNH) at $400.3B 2024 revenue with UnitedHealthcare + Optum; 2025 leadership transition (Hemsley return, Witty departure) and suspended outlook after Change Healthcare breach and elevated medical costs.
About
UnitedHealth Group is a Minnetonka, Minnesota-based healthcare and insurance conglomerate — publicly traded on the New York Stock Exchange (NYSE: UNH) as the largest healthcare company in the United States by revenue — reporting $400.3 billion in 2024 revenues and operating through two complementary platforms: UnitedHealthcare (health insurance serving 50+ million people) and Optum (health services including OptumHealth care delivery, OptumRx pharmacy benefit management, and OptumInsight technology and analytics). Employing approximately 400,000 people globally across 500+ locations, UnitedHealth Group has been transformed by a turbulent 2024-2025 period: the Change Healthcare ransomware cyberattack (February 2024) disrupted healthcare payments for 190 million Americans; UnitedHealthcare CEO Brian Thompson was murdered in December 2024 in New York City; and CEO Andrew Witty resigned for personal reasons in May 2025, with founder-era CEO Stephen Hemsley returning to lead the company and the 2025 earnings outlook suspended amid higher-than-expected medical costs.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.